MX337393B - Forma salina de un conjugado de polímero-farmaco con multiples brazos. - Google Patents
Forma salina de un conjugado de polímero-farmaco con multiples brazos.Info
- Publication number
- MX337393B MX337393B MX2012005795A MX2012005795A MX337393B MX 337393 B MX337393 B MX 337393B MX 2012005795 A MX2012005795 A MX 2012005795A MX 2012005795 A MX2012005795 A MX 2012005795A MX 337393 B MX337393 B MX 337393B
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugate
- salt form
- arm polymer
- conjugate
- hydrohalide salt
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 3
- 239000000580 polymer-drug conjugate Substances 0.000 title 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 polyethylene Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Support Of Aerials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26246309P | 2009-11-18 | 2009-11-18 | |
| US29007209P | 2009-12-24 | 2009-12-24 | |
| PCT/US2010/057292 WO2011063158A1 (en) | 2009-11-18 | 2010-11-18 | Salt form of a multi-arm polymer-drug conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012005795A MX2012005795A (es) | 2012-09-07 |
| MX337393B true MX337393B (es) | 2016-03-02 |
Family
ID=43639124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005795A MX337393B (es) | 2009-11-18 | 2010-11-18 | Forma salina de un conjugado de polímero-farmaco con multiples brazos. |
| MX2012005794A MX338134B (es) | 2009-11-18 | 2010-11-18 | Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005794A MX338134B (es) | 2009-11-18 | 2010-11-18 | Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion. |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20130143909A1 (https=) |
| EP (3) | EP2501413B1 (https=) |
| JP (3) | JP5901073B2 (https=) |
| KR (2) | KR101779229B1 (https=) |
| CN (2) | CN102711837B (https=) |
| AU (1) | AU2010321882B2 (https=) |
| BR (2) | BR112012011947B8 (https=) |
| CA (3) | CA2780645C (https=) |
| CY (1) | CY1121700T1 (https=) |
| DK (1) | DK2501413T3 (https=) |
| EA (2) | EA023503B1 (https=) |
| ES (2) | ES2723026T3 (https=) |
| HR (1) | HRP20191138T1 (https=) |
| HU (1) | HUE043689T2 (https=) |
| IL (2) | IL219865A (https=) |
| LT (1) | LT2501413T (https=) |
| ME (1) | ME03396B (https=) |
| MX (2) | MX337393B (https=) |
| PL (1) | PL2501413T3 (https=) |
| PT (1) | PT2501413T (https=) |
| RS (1) | RS58901B1 (https=) |
| SI (1) | SI2501413T1 (https=) |
| SM (1) | SMT201900294T1 (https=) |
| WO (2) | WO2011063158A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| PT2501413T (pt) | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| EP2771034B1 (en) * | 2011-10-25 | 2018-08-08 | Nektar Therapeutics | Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer |
| AU2013253098A1 (en) * | 2012-04-26 | 2014-11-13 | Amylex Pharmaceuticals, Inc | Novel composition for extracorporeal reduction of Beta-Amyloids and process for producing thereof |
| JP6300460B2 (ja) * | 2012-07-20 | 2018-03-28 | キヤノン株式会社 | 化合物、および前記化合物を有する光音響イメージング用造影剤 |
| US9421276B2 (en) * | 2012-08-31 | 2016-08-23 | Virginia Commonwealth University | Clickable polyoxetane carrier for drug delivery |
| WO2014085571A1 (en) | 2012-11-28 | 2014-06-05 | Nektar Therapeutics | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor |
| US9493766B2 (en) * | 2013-02-04 | 2016-11-15 | Corning Incorporated | PCR reaction cleanup buffers |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| WO2014194289A1 (en) | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| CN104225611B (zh) * | 2013-06-18 | 2017-06-30 | 天津键凯科技有限公司 | 达沙替尼与非线性构型聚乙二醇的结合物 |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| JP5721806B2 (ja) * | 2013-10-04 | 2015-05-20 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 副作用のない抗癌剤 |
| MX371201B (es) * | 2013-10-04 | 2020-01-22 | Prolynx Llc | Conjugados de liberación lenta de sn-38. |
| MX386070B (es) | 2014-01-14 | 2025-03-18 | Nektar Therapeutics | Metodo de tratamiento basado en combinacion. |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3228650B1 (en) * | 2014-12-04 | 2022-03-09 | Delta-Fly Pharma, Inc. | Novel peg derivative |
| WO2016124976A1 (en) * | 2015-02-04 | 2016-08-11 | United Arab Emirates University | Rvg derived peptides |
| WO2017027843A1 (en) | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| CN107019803B (zh) * | 2016-01-29 | 2020-09-15 | 北京键凯科技股份有限公司 | 具有低成瘾作用的聚乙二醇化阿片样物质 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| CN107469089B (zh) | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | 一种peg连接子及配基药物偶联物 |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| KR102619747B1 (ko) | 2017-01-10 | 2023-12-29 | 넥타르 테라퓨틱스 | Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법 |
| CN110235003B (zh) * | 2017-02-02 | 2022-04-01 | 阿尔卑斯阿尔派株式会社 | 平衡式电流传感器 |
| CN108727584B (zh) * | 2017-04-21 | 2021-01-05 | 博瑞生物医药（苏州）股份有限公司 | 抗癌偶联物 |
| KR102279429B1 (ko) | 2017-04-21 | 2021-07-20 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 멀티 암 표적 항암 콘쥬게이트 |
| WO2019046452A1 (en) * | 2017-09-01 | 2019-03-07 | Arizona Board Of Regents On Behalf Of Arizona State University | THIXOTROPIC BIOCOMPATIBLE GEL FOR OBSERVATION OF LIVING CELLS IN COMPUTER-ASSISTED TOMOGRAPHY ON CELLS |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| WO2019096096A1 (zh) * | 2017-11-14 | 2019-05-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| CN107854693B (zh) * | 2017-11-14 | 2020-07-14 | 高瑞耀业(北京)科技有限公司 | 整合素受体靶向的抗癌偶联物 |
| CN109776787B (zh) * | 2017-11-14 | 2021-08-03 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| WO2019131515A1 (ja) | 2017-12-27 | 2019-07-04 | 三洋化成工業株式会社 | 医薬品原薬用原料又は医薬品用添加物及びこれらを用いた医薬品原薬又は医薬品 |
| MX2020007442A (es) * | 2018-01-12 | 2020-09-14 | Prolynx Llc | Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion. |
| MX2020007971A (es) | 2018-01-31 | 2020-09-09 | Univ Minnesota | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. |
| CN110256533B (zh) * | 2018-03-12 | 2022-05-10 | 博瑞生物医药（苏州）股份有限公司 | 一种高纯度的多臂抗癌偶联物的提取方法 |
| CN110577552A (zh) * | 2018-06-08 | 2019-12-17 | 遵义医学院 | 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用 |
| CA3112778A1 (en) | 2018-09-17 | 2020-03-26 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| JP2022545402A (ja) * | 2019-08-15 | 2022-10-27 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 腫瘍関連エキソソームの免疫抑制をブロックするホスファチジルセリン結合分子 |
| EP4126104A4 (en) | 2020-03-27 | 2024-04-17 | Regents of the University of Minnesota | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR PNEUMATIC INFLAMMATION |
| CN114705801B (zh) * | 2022-01-24 | 2024-02-27 | 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) | 一种利福霉素类药物中亚硝酸根离子的测定方法 |
| CN121843719A (zh) * | 2023-09-08 | 2026-04-10 | 法罗斯根有限公司 | 在制备抗癌剂前药偶联物中回收和去除钯的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1222261B (de) * | 1963-04-20 | 1966-08-04 | Bayer Ag | Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden |
| GB1157753A (en) * | 1966-06-24 | 1969-07-09 | Bp Chem Int Ltd | Improvements in or relating to Synthetic Lubricants |
| JPS6019790A (ja) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5399728A (en) * | 1993-04-05 | 1995-03-21 | Arco Chemical Technology, L.P. | Process for the preparation of highly esterified alkoxylated polyol compositions |
| GB9704126D0 (en) * | 1997-02-27 | 1997-04-16 | Ici Plc | Surfactants |
| DE19817676A1 (de) * | 1998-04-21 | 1999-10-28 | Bayer Ag | Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| DE19937114C2 (de) | 1999-08-06 | 2003-06-18 | Bayer Ag | Verfahren zur Herstellung von Polyetherpolyolen |
| US6762325B2 (en) | 2001-05-16 | 2004-07-13 | Nippon Shokubai Co., Ltd. | Method for production of alkoxylated compound |
| SE523934C2 (sv) * | 2001-09-24 | 2004-06-01 | Perstorp Specialty Chem Ab | Förfarande för av alkoxylering av di-, tri och polyalkoholer |
| US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| KR20050051686A (ko) * | 2002-10-09 | 2005-06-01 | 인설트 테라페틱스, 인코퍼레이티드 | 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도 |
| US20050043215A1 (en) * | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| EP2644206B1 (en) * | 2003-05-23 | 2019-04-03 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
| CA2537336C (en) * | 2003-09-17 | 2013-02-26 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| KR101276422B1 (ko) * | 2004-03-15 | 2013-06-19 | 넥타르 테라퓨틱스 | Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 |
| US7897772B2 (en) * | 2004-10-01 | 2011-03-01 | Kabushiki Kaisha Yakult Honsha | Acid addition salt of irinotecan |
| WO2006110776A2 (en) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Polyethylene glycol cojugates of antimicrobial agents |
| US8568705B2 (en) * | 2005-07-18 | 2013-10-29 | Nektar Therapeutics | Method for preparing branched functionalized polymers using branched polyol cores |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| JP5105166B2 (ja) * | 2007-12-19 | 2012-12-19 | 公益財団法人野口研究所 | ポリエーテルの製造方法 |
| PT2501413T (pt) | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
-
2010
- 2010-11-18 PT PT10782159T patent/PT2501413T/pt unknown
- 2010-11-18 ES ES10782159T patent/ES2723026T3/es active Active
- 2010-11-18 PL PL10782159T patent/PL2501413T3/pl unknown
- 2010-11-18 WO PCT/US2010/057292 patent/WO2011063158A1/en not_active Ceased
- 2010-11-18 HR HRP20191138TT patent/HRP20191138T1/hr unknown
- 2010-11-18 WO PCT/US2010/057289 patent/WO2011063156A2/en not_active Ceased
- 2010-11-18 BR BR112012011947A patent/BR112012011947B8/pt active IP Right Grant
- 2010-11-18 SI SI201031891T patent/SI2501413T1/sl unknown
- 2010-11-18 CA CA2780645A patent/CA2780645C/en active Active
- 2010-11-18 JP JP2012540065A patent/JP5901073B2/ja active Active
- 2010-11-18 EP EP10782159.7A patent/EP2501413B1/en active Active
- 2010-11-18 KR KR1020127015273A patent/KR101779229B1/ko active Active
- 2010-11-18 CA CA2780779A patent/CA2780779C/en active Active
- 2010-11-18 JP JP2012540064A patent/JP5951496B2/ja active Active
- 2010-11-18 BR BR112012011943-5A patent/BR112012011943A2/pt not_active Application Discontinuation
- 2010-11-18 DK DK10782159.7T patent/DK2501413T3/da active
- 2010-11-18 ME MEP-2019-185A patent/ME03396B/me unknown
- 2010-11-18 EP EP10781794.2A patent/EP2501412B1/en active Active
- 2010-11-18 EP EP19152138.4A patent/EP3498754A1/en active Pending
- 2010-11-18 US US13/510,555 patent/US20130143909A1/en not_active Abandoned
- 2010-11-18 AU AU2010321882A patent/AU2010321882B2/en active Active
- 2010-11-18 RS RS20190781A patent/RS58901B1/sr unknown
- 2010-11-18 MX MX2012005795A patent/MX337393B/es active IP Right Grant
- 2010-11-18 CN CN201080061613.6A patent/CN102711837B/zh active Active
- 2010-11-18 HU HUE10782159A patent/HUE043689T2/hu unknown
- 2010-11-18 LT LTEP10782159.7T patent/LT2501413T/lt unknown
- 2010-11-18 US US13/510,587 patent/US9226969B2/en active Active
- 2010-11-18 CA CA3063465A patent/CA3063465C/en active Active
- 2010-11-18 CN CN201080061609.XA patent/CN102711836B/zh active Active
- 2010-11-18 KR KR1020127015272A patent/KR101790804B1/ko active Active
- 2010-11-18 EA EA201200751A patent/EA023503B1/ru unknown
- 2010-11-18 SM SM20190294T patent/SMT201900294T1/it unknown
- 2010-11-18 MX MX2012005794A patent/MX338134B/es active IP Right Grant
- 2010-11-18 EA EA201290342A patent/EA024533B1/ru unknown
- 2010-11-18 ES ES10781794.2T patent/ES2623677T3/es active Active
-
2012
- 2012-05-17 IL IL219865A patent/IL219865A/en active IP Right Grant
- 2012-05-17 IL IL219866A patent/IL219866A/en active IP Right Grant
-
2014
- 2014-05-21 US US14/284,067 patent/US9320808B2/en active Active
-
2015
- 2015-10-07 JP JP2015199074A patent/JP2016006127A/ja active Pending
-
2016
- 2016-03-21 US US15/075,750 patent/US20160200867A1/en not_active Abandoned
-
2019
- 2019-06-18 CY CY20191100623T patent/CY1121700T1/el unknown
-
2020
- 2020-10-02 US US17/062,457 patent/US11834553B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337393B (es) | Forma salina de un conjugado de polímero-farmaco con multiples brazos. | |
| AU335660S (en) | A bowl | |
| AU332502S (en) | Cloth | |
| AU327564S (en) | Handset | |
| AU332147S (en) | Divided dish | |
| AU331113S (en) | Handset | |
| AU331112S (en) | Handset | |
| AU332381S (en) | Handset | |
| AU332382S (en) | Handset | |
| AU329410S (en) | Handset | |
| AU332501S (en) | Pad | |
| AU327424S (en) | Mop | |
| AU331526S (en) | Mobile phone | |
| AU327541S (en) | Handset | |
| AU335448S (en) | Chair | |
| MX2011011767A (es) | Combinacion antitumoral que comprende ave8062 y sorafenib. | |
| AU328360S (en) | Supporting base | |
| AU327562S (en) | Handset | |
| AU324833S (en) | Rocker leg | |
| CA138498S (en) | Rodent bait station | |
| AU329146S (en) | Rodent bait station | |
| AU329199S (en) | Luminaire | |
| AU327061S (en) | A digging point | |
| AU327059S (en) | A digging point | |
| AU327207S (en) | A digging point |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |